Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · IEX Real-Time Price · USD
4.000
-0.280 (-6.54%)
At close: May 17, 2024, 4:00 PM
3.930
-0.070 (-1.75%)
After-hours: May 17, 2024, 4:42 PM EDT
Prelude Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for PRLD stock have an average target of 5.25, with a low estimate of 4.00 and a high estimate of 7.00. The average target predicts an increase of 31.25% from the current stock price of 4.00.
Analyst Consensus: Hold
* Price targets were last updated on Mar 13, 2024.
Analyst Ratings
The average analyst rating for PRLD stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Initiates $7 | Buy | Initiates | $7 | +75.00% | Mar 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $5 | Strong Buy → Hold | Downgrades | $5 | +25.00% | Feb 20, 2024 |
| Morgan Stanley | Morgan Stanley | Hold → Sell Downgrades $10 → $4 | Hold → Sell | Downgrades | $10 → $4 | n/a | Dec 19, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +25.00% | Nov 7, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $17 → $6 | Strong Buy | Maintains | $17 → $6 | +50.00% | Oct 19, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.04
from -2.02
EPS Next Year
-1.65
from -2.04
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | n/a | 39.8M |
| Avg | n/a | n/a | n/a | n/a | 38.6M |
| Low | n/a | n/a | n/a | n/a | 37.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.92 | -1.28 | -1.71 | -1.47 | -1.24 |
| Avg | -2.04 | -1.65 | -1.66 | -1.43 | -1.20 |
| Low | -2.18 | -1.85 | -1.60 | -1.37 | -1.16 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.